Serial Innovation to Bring Transformative Precision Medicines to People with Serious Diseases: A Conversation with Jeffrey Leiden, MD, PhD

Jeffrey Leiden, John D. Rutherford

Research output: Contribution to journalReview article

Abstract

Dr Leiden received his BA, MD, and PhD degrees with honors from the University of Chicago. He completed his Internship, Residency, and Cardiology Fellowship training at the Brigham and Women’s Hospital, became a Howard Hughes Investigator at the University of Michigan, and then returned to the University of Chicago for 7 years as Chief of Cardiology. He returned to Harvard as the Elkan R. Blout Professor of Biological Sciences in the School of Public Health and Professor of Medicine at Harvard Medical School. From 2000 to 2006, he served as President, Chief Operating Officer, and Chief Scientific Officer at Abbott Laboratories. From 2006 to 2011, he was Managing Director of Clarus Ventures and then became Chairman and Chief Executive Officer of Vertex. He is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Medicine.

Original languageEnglish (US)
Pages (from-to)108-113
Number of pages6
JournalCirculation
Volume142
Issue number2
DOIs
StatePublished - Jul 14 2020

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Serial Innovation to Bring Transformative Precision Medicines to People with Serious Diseases: A Conversation with Jeffrey Leiden, MD, PhD'. Together they form a unique fingerprint.

  • Cite this